Hypera (HYPE3) Q4 2024 earnings summary

Executive summary

• Net revenue for 2024 was R$7,442.5 million, down 6.0% year-over-year, while sell-out grew 9.3% (25.5% in non-retail, 8.1% in retail), driven by portfolio acceleration and institutional market strength.

• Net income from continuing operations declined 19.4% to R$1,330.9 million, mainly due to lower EBIT from capital optimization.

• Record operating cash flow reached R$2,539.6 million (+6.0% YoY), and free cash flow was R$1,760.8 million (+20.7% YoY), supported by inventory and receivable reductions.

• Over R$2.3 billion invested in marketing, innovation, and production/distribution capacity, with more than 50 product launches and expansion of the Anápolis distribution center.

• R$738.9 million distributed to shareholders as dividends and interest on equity (6.5% yield).

Financial highlights

• Gross margin was 58.9% for 2024 (down 4.2 p.p.), and 52.0% in 4Q24; gross profit was R$4,381.0 million (-12.3% YoY).

• EBITDA from continuing operations was R$2,101.0 million (28.2% margin), down 23.8% year-over-year; 4Q24 EBITDA margin was 9.1%.

• Net debt post-hedge was R$7,501.1 million at year-end, with leverage ratio at 38.3%.

• Dividend yield was 6.5% for 2024.

• Marketing expenses increased 6.7% year-over-year, with a 210bps rise as a percentage of net revenue.

Outlook and guidance

• Working capital optimization is expected to conclude in 2025, aligning inventory levels with industry standards and supporting sustainable growth and improved return on invested capital.

• Margin recovery and normalized operations are expected in the second half of 2024, with continued innovation pipeline and entry into molecules losing patent protection.

• Market expects 10.2% growth for the Brazilian pharma sector in 2025, with positive demographic and chronic disease trends.